160 related articles for article (PubMed ID: 23917385)
1. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
[No Abstract] [Full Text] [Related]
2. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.
Escandell I; Cabezas M; Martín JM; Terradez L; Pinazo MI
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1224-6. PubMed ID: 25917403
[No Abstract] [Full Text] [Related]
4. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
5. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
[No Abstract] [Full Text] [Related]
6. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
Zaloum A; Falet JR; Elkrief A; Chalk C
Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
[No Abstract] [Full Text] [Related]
7. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
8. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
[No Abstract] [Full Text] [Related]
9. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
10. GSK drug combination approved for advanced melanoma.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
[No Abstract] [Full Text] [Related]
11. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
[No Abstract] [Full Text] [Related]
12. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
Lim J; Lomax AJ; McNeil C; Harrisberg B
Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
[TBL] [Abstract][Full Text] [Related]
13. [A woman with a skin lesion suspected for melanoma].
Post NF; Huis In 't Veld E; Crijns MB
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267633
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
15. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.
Mistry HB; Orrell D; Eftimie R
Cancer Chemother Pharmacol; 2018 Feb; 81(2):325-332. PubMed ID: 29222604
[TBL] [Abstract][Full Text] [Related]
16. Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy.
Harrison SR; Tew A; Steven N; Fisher BA
Rheumatology (Oxford); 2018 Aug; 57(8):1497-1499. PubMed ID: 29617934
[No Abstract] [Full Text] [Related]
17. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib.
Shimada S; Fukushima S; Niimori D; Miyashita A; Setoyama H; Sasaki Y; Ihn H
J Dermatol; 2018 Jun; 45(6):e157-e158. PubMed ID: 29315749
[No Abstract] [Full Text] [Related]
18. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
19. Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib.
Martínez-Rodríguez I; García-Castaño A; Quirce R; Jiménez-Bonilla J; Banzo I
Clin Nucl Med; 2017 Jan; 42(1):44-46. PubMed ID: 27775948
[TBL] [Abstract][Full Text] [Related]
20. Complete response for 36 months after BRAF and MEK inhibitor therapy for locally advanced gallbladder melanoma.
Hakim S; Orosey M; Edhi A; Amin M; Cappell MS
Minerva Gastroenterol Dietol; 2019 Sep; 65(3):243-246. PubMed ID: 31115206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
